نتایج جستجو برای: idiopathic membranous nephropathy

تعداد نتایج: 94794  

Journal: :nephro-urology monthly 0
hamidreza omrani nephrology and urology research center, kermanshah university of medical sciences, kermanshah, iran sima golmohamadi nephrology and urology research center, kermanshah university of medical sciences, kermanshah, iran; nephrology and urology research center, kermanshah university of medical sciences, kermanshah, iran. tel: +98-9185960644, fax: +98-8334282668 fateme hichi department of internal medicine, kermanshah university of medical sciences, kermanshah, iran masoud sadeghi medical biology research center, kermanshah university of medical sciences, kermanshah, iran

conclusions cyclosporine and tacrolimus reduce proteinuria and serum creatinine after 6 months. nonetheless, tacrolimus reduces urea and cyclosporine increases it. however, since the prevalence of the side effects of both drugs is similar, tacrolimus has better results in the treatment of imn patients compared with cyclosporine. background immunosuppressive drugs have received the most attentio...

Journal: :Clinical journal of the American Society of Nephrology : CJASN 2006
Piero Ruggenenti Carlos Chiurchiu Mauro Abbate Annalisa Perna Paolo Cravedi Mario Bontempelli Giuseppe Remuzzi

Rituximab effectively reduces proteinuria in patients with idiopathic membranous nephropathy (IMN), but response to treatment may vary from patient to patient. The association between baseline clinical, laboratory, and histology covariates and proteinuria reduction was evaluated retrospectively by multiple linear regression analysis at 3 mo after rituximab therapy in 14 patients with IMN with p...

Journal: :Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2007
Yoshihiro Matsumoto Chiewei Lee Seiji Shimada

lies in the way information on ACEI/ARB treatment was obtained. In the study of Opelz et al., a questionnaire was sent out, with a return rate of 107 out of 299 participating centres. Their publication does not provide information on how completely the data was collected within those 107 centres. By contrast, we used data bases from the general public Austrian Sickness Funds and direct entry fr...

2015
Jennie Lönnbro-Widgren Kerstin Ebefors Johan Mölne Jenny Nyström Börje Haraldsson

BACKGROUND In idiopathic membranous nephropathy (MN), antibodies directed towards the glomerular phospholipase A2 receptor (PLA2R) have mainly been reported to be of IgG4 subclass. However, the role of the different IgG subclasses in the pathogenesis of MN, both in idiopathic MN and in secondary cases, is still unclear. In this retrospective study, we test the hypothesis that the absence of glo...

Journal: :Clinical journal of the American Society of Nephrology : CJASN 2010
Fernando C Fervenza Roshini S Abraham Stephen B Erickson Maria Valentina Irazabal Alfonso Eirin Ulrich Specks Patrick H Nachman Eric J Bergstralh Nelson Leung Fernando G Cosio Marie C Hogan John J Dillon LaTonya J Hickson Xujian Li Daniel C Cattran

BACKGROUND AND OBJECTIVES It was postulated that in patients with membranous nephropathy (MN), four weekly doses of Rituximab (RTX) would result in more effective B cell depletion, a higher remission rate, and maintaining the same safety profile compared with patients treated with RTX dosed at 1 g every 2 weeks. This hypothesis was supported by previous pharmacokinetic (PK) analysis showing tha...

2014
Edward J. Filippone

Idiopathic membranous nephropathy (iMN) is a single-organ autoimmune disease characterized by subepithelial deposition of immune complexes containing IgG4 resulting in proteinuria, nephrotic syndrome, and, in some, end-stage renal disease. The pathogenesis involves a chronic IgG4 response against specific podocyte antigens which have now been at least partially defined in the neonatal, early ch...

Journal: :Journal of the American Society of Nephrology : JASN 2003
Piero Ruggenenti Carlos Chiurchiu Varusca Brusegan Mauro Abbate Annalisa Perna Claudia Filippi Giuseppe Remuzzi

Currently available monoclonal antibodies against the B cell surface antigen CD20 have been employed to explore whether specific inhibition of B cells may help improve the outcome of idiopathic membranous nephropathy (IMN) and may avoid the side effects of steroids and immunosuppressants. This prospective, observational study evaluated the 1-yr outcome of eight IMN patients with persistent (>6 ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید